Sample link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/82

Key Highlights:
• In July 2021, Roche has launched a spinal muscular atrophy (SMA) treatment drug in India priced at around 6lakhper bottle. The drug Evrysdi is approved for the treatment of SMA in adults and children 2 months of age and older, Roche said it was approved by the Indian health authorities after reviewing its efficacy and safety data from 3 global clinical studies designed to represent a broad spectrum of people living with SMA.
• In July 2021, SadBaby has pledged to help SMA (Spinal Muscular Atrophy) patients in improving their life and ensuring that no child is left uncured. The project launched by SadBaby focuses on gathering funds through their supporters and investors and utilizes it for meeting the financial requirements of the SMA patients.